PRRT2 and neoplasm: These inducers trigger a unique form of cell death that operates independently of other treatment mechanisms, such as those targeted by darovasertib, a PKC inhibitor, and crizotinib, a c-Met inhibitor, which have shown significant efficacy in reducing tumor size in Phase II trials (Cao et al., 2023).